Results 141 to 150 of about 268,869 (312)

Synergistic Effects of Normal‐Range Serum Sodium and Potassium on Mortality: The Modifying Role of Inflammation From a NHANES Cohort Analysis

Chronic Diseases and Translational Medicine, EarlyView.
Nonlinear associations of serum sodium levels with cardiovascular (A) and all‐cause mortality (B)among 32,837 adults. Nonlinear associations of serum potassium levels with cardiovascular (C) and all‐cause mortality (D) among 32,837 adults. ABSTRACT Background This study aimed to investigate the associations of serum sodium and potassium levels within ...
Haofeng Zhang, Fudong He, Zhenger Fang, Guangjun Zheng, Biying Zhou, Xia Chen, Mingliang Liu, Guang Hao   +7 more
wiley   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and Cancer Risk: Insights from a Large Propensity‐Matched Cohort Study

Clinical Pharmacology &Therapeutics, EarlyView.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) lower LDL cholesterol and may influence cancer through immunomodulatory pathways. However, their effect on human cancer incidence remains unknown. We conducted a retrospective, propensity score‐matched study (Clalit Health Services, Israel, 2010–2023) comparing PCSK9 ...
Inbar Nardi Agmon, Chen Gurevitz, Tzippy Shochat, Shiri Kushnir, Guy Witberg, Amos Levi, Dan Gilon, Ran Kornowski, Paaladinesh Thavendiranathan, Husam Abdel Qadir, Zaza Iakobishvili   +10 more
wiley   +1 more source

NAFLD‐related hepatocellular carcinoma: The growing challenge

Hepatology, EarlyView., 2022
Risk and protective factors for NAFLD‐related hepatocellular carcinoma Abstract Hepatocellular carcinoma (HCC) is a common cause of cancer‐related mortality and morbidity worldwide. With the obesity pandemic, NAFLD‐related HCC is contributing to the burden of disease exponentially.
Pir Ahmad Shah, Rashmee Patil, Stephen A. Harrison   +2 more
wiley   +1 more source

Implementation of OMOP and ConcePTION Common Data Models in CPRD GOLD: Risk of Bleeding and Cardiovascular Outcomes From Anticoagulant Use

Clinical Pharmacology &Therapeutics, EarlyView.
The impact of the choice of common data model (CDM) approach on the study results in a real‐world evidence (RWE) study is unknown. We aimed to determine potential differences in the results of an RWE study when data were mapped to two different CDMs, ConcePTION and OMOP. With the same instance of CPRD GOLD, data were mapped to both CDMs. Using the same
Nicholas B. Hunt, Patrick Souverein, Marloes Bazelier, Nicola Barclay, Antonella Delmestri, Miriam Sturkenboom, Daniel Prieto‐Alhambra, Helga Gardarsdottir, Olaf Klungel   +8 more
wiley   +1 more source

Angiotensin II Directly Increases Endothelial Calcium and Nitric Oxide in Kidney and Brain Microvessels In Vivo With Reduced Efficacy in Hypertension

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background The vasoconstrictor effects of angiotensin II via type 1 angiotensin II receptors in vascular smooth muscle cells are well established, but the direct effects of angiotensin II on vascular endothelial cells (VECs) in vivo and the mechanisms ...
Alejandra Becerra Calderon, Urvi Nikhil Shroff, Sachin Deepak, Audrey Izuhara, Greta Trogen, Alicia A. McDonough, Susan B. Gurley, Jonathan W. Nelson, János Peti‐Peterdi, Georgina Gyarmati   +9 more
doaj   +1 more source

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

Clinical Pharmacology &Therapeutics, EarlyView.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, Tyler Shugg   +10 more
wiley   +1 more source

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis

Hepatology, EarlyView., 2022
Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres, Cristina Ortiz, Nadine Bachtler, Wenyi Gu, Leon D. Grünewald, Nico Kraus, Robert Schierwagen, Christoph Hieber, Caroline Meier, Olaf Tyc, Maximilian Joseph Brol, Frank Erhard Uschner, Bart Nijmeijer, Christoph Welsch, Marie‐Luise Berres, Carmen Garcia‐Ruiz, Jose Carlos Fernandez‐Checa, Christian Trautwein, Thomas J. Vogl, Stefan Zeuzem, Jonel Trebicka, Sabine Klein   +21 more
wiley   +1 more source

The role of the classical renin–angiotensin system and angiotensin-converting enzyme 2/Ang(1–7)/Mas axis in pulmonary fibrosis

Frontiers in Medicine
Pulmonary fibrosis (PF), a progressive and fatal disease, is characterized by fibroblast proliferation, excessive extracellular matrix deposition, and collagen synthesis. These pathological changes lead to impaired lung structure and function, ultimately
Changhui Lang, Changhui Lang, Bo Huang, Bo Huang, Yan Chen, Yan Chen, Zhixu He, Zhixu He   +7 more
doaj   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

The angiotensin II type 2 receptor and the kidney

Journal of the Renin-Angiotensin-Aldosterone System, 2009
Recent knowledge demonstrated that the renin-angiotensin system (RAS) functions as a local renal paracrine system. All components of the RAS are present within the kidney and include angiotensinogen, renin, angiotensin I, angiotensin-converting enzymes, angiotensin II, the angiotensin II type 1 (AT1) receptor and the angiotensin II type 2 (AT2 ...
openaire   +2 more sources